Skip to main content

Boyd Peter E.'s Form 4 filing

Aquestive Therapeutics, Inc.AQST · filed Jun 10, 2022

Accession no.
0001628280-22-016872
Filed
Jun 10, 2022, 5:26 PM ET
Trade date
Jun 8, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $2.20K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Boyd Peter E.CIK 0001739816Officer (SVP-Bus. Process & Info. Tech.)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 8, 2022Common StockPPurchaseAcquired+2,293$0.96F1+$2,201.2854,532Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jun 8, 2022Common StockPPurchaseAcquired+2,293$0.13F1+$298.092,293Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each share of common stock sold to the Reporting Person was sold together with one warrant to purchase one share of common stock at a price per share of $1.09 per share and warrant, of which the price per share of common stock was deemed to be $0.96 and the price per warrant was deemed to be $0.13

Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.

Read the full filing on SEC EDGAR (opens in a new tab)